Soleno Therapeutics (SLNO) Cash & Equivalents (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Cash & Equivalents data on file, last reported at $133.0 million in Q1 2026.

• Quarterly Cash & Equivalents rose 63.56% year-over-year to $133.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.0 million (up 63.56% YoY) and the FY2025 annual result came in at $70.1 million, down 20.27% from the prior year.
• Cash & Equivalents advanced to $133.0 million in Q1 2026 per SLNO's latest filing, from $70.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $246.7 million in Q3 2025 and bottomed at $7.9 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $52.4 million (2023), against an average of $69.4 million.
• Peak annual rise in Cash & Equivalents reached 1062.04% in 2023, while the deepest fall reached 72.76% in 2023.
• Tracing SLNO's Cash & Equivalents over 5 years: stood at $14.6 million in 2022, then soared by 1062.04% to $169.7 million in 2023, then sank by 48.18% to $87.9 million in 2024, then slipped by 20.27% to $70.1 million in 2025, then jumped by 89.75% to $133.0 million in 2026.
• Per Business Quant, the three latest SLNO Cash & Equivalents figures stand at $133.0 million (Q1 2026), $70.1 million (Q4 2025), and $246.7 million (Q3 2025).

Peer Comparison